+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects



Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects



Drugs and Aging 2(3): 208-221



Topical beta-blockers reduce the intraocular pressure (IOP) by blockade of sympathetic nerve endings in the ciliary epithelium causing a fall in aqueous humour production. Two types of topical beta-blockers are available for use in glaucoma: nonselective, which block both beta 1- and beta 2-adrenoceptors; and cardioselective, which block only beta 1-receptors. Of the beta-Blockers commercially available, timolol, levobunolol, metipranolol and carteolol are nonselective, and betaxolol is cardioselective. Twice-daily timolol is probably the most effective agent in lowering IOP, although levobunolol is equally effective and can be used once daily with little difference in effect. Carteolol is used twice daily and any theoretical advantage in diminished side effects conferred by its partial beta-agonist activity compared with timolol has not been fully substantiated. Metipranolol is effective twice daily and does not have partial beta-agonist activity. Betaxolol has an effect comparable to timolol in lowering IOP, but is less effective in some patients. beta-Blockers can be used with other antiglaucoma medications, but their combined action with epinephrine (adrenaline) is suspect, particularly in the case of the nonselective beta-blockers, and the effect should be assessed in patients on an individual basis. Local stinging can be a problem in some patients with betaxolol. The most serious side effects of beta-blockers are the exacerbation of chronic obstructive airways disease with nonselective agents and the precipitation of bronchospasm in some patients. Betaxolol seems relatively free of adverse respiratory effects, although this may be dose-related and extreme caution should still be exercised in patients with any history of respiratory illness. Because of the lower risk of precipitating side effects, betaxolol is probably the beta-blocker of first choice for use in glaucoma; timolol or levobunolol are reserved for patients who do not respond satisfactorily to betaxolol and are quite free of respiratory disease.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 040850900

Download citation: RISBibTeXText

PMID: 1351412


Related references

Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. Drugs and Aging 12(3): 225-241, 1998

Primary drug treatment for glaucoma Beta-blockers versus other medications II Choosing beta-blockers for initial medical therapy for glaucoma. Survey of Ophthalmology 47(1): 68-73, January-February, 2002

Topical beta blockers for glaucoma an investigation of ocular hypotensive efficacy vis a vis systemic beta blockade. Clinical Pharmacology & Therapeutics 37(2): 218, 1985

Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension. Drugs and Aging 9(5): 363-378, 1996

Frequency of Contraindications to the Use of Ocular Beta-blockers in Patients at a University General and Glaucoma Eye Clinic. ARVO Annual Meeting Abstract Search & Program Planner : Abstract No 4077, 2002

Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension. Clinical Therapeutics 23(4): 604-619, 2001

Beta-blockers--pharmacological and haemodynamic aspects. Australian and New Zealand Journal of Medicine 6(3 Suppl.): 27-28, 1976

A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension. Journal of Ocular Pharmacology and Therapeutics 20(5): 383-392, 2004

Medical management of glaucoma beta blockers. CLAO Journal 17(2): 132-133, 1991

Effects of long-term hypotensive therapy with nonselective beta-blockers on ocular hemodynamics in primary open-angle glaucoma. Journal of Glaucoma 8(1): 12-17, 1999

The effects of beta-blockers on ocular blood flow in patients with primary open angle glaucoma: a color Doppler imaging study. European Journal of Ophthalmology 11(1): 37-46, 2001

Costs and persistence of carbonic anhydrase inhibitor versus alpha-2 agonists, associated with beta-blockers, in glaucoma and ocular hypertension: an analysis of the UK-GPRD database. Current Medical Research and Opinion 24(5): 1519-1527, 2008

Longterm effect of topical beta-blockers on intraocular pressure and visual field sensitivity in ocular hypertension and chronic open-angle glaucoma. Survey of Ophthalmology 38 Suppl: S149-S155, 1994

Comparison of the efficacy and tolerability of Alphagan and Trusopt as adjunct therapy with beta-blockers in patients with chronic open-angle glaucoma or ocular hypertension. IOVS 41(4): S753, 2000

Clinical pharmacology of beta blockers and its use for the treatment of glaucoma. Annali di Ottalmologia e Clinica Oculistica 119(6): 501-505, 1993